stockrow
Saturday 7 November 2026
Export IGC’s income statement to Excel — free account
IGC Pharma, Inc.
IGC Pharma, Inc.’s revenue for fiscal 2025 (year ended March 2025) was $1.3 million, down 5.50% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- 0.00%
- Free cash flow
- −45.3%
- Total debt
- +558.3%
Quarter to September 2026, against a year earlier
0.19
0.00
0.00%
Follow IGC
Alert me
| Sep '26 From the 10-Q filed 6 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (126.16%) | (143.46%) | (112.76%) | 0.00% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
2 | 1 | 1 | — | |
| (94.55%) | (100.44%) | (78.30%) | 0.00% | ||
ROIC |
(90.48%) | (91.53%) | (79.70%) | 0.00% | |
Return on Tangible Assets |
(3,883.97%) | (7,422.03%) | (1,862.07%) | 0.00% | |
Average Days of Receivables |
22.54 | 18.56 | 11.58 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.06) | (0.04) | — | |
Free Cash Flow |
(5.35) | (5.69) | (4.08) | — | |
Capital Expenditures |
— | (0.35) | 0.64 | — | |
| Other line items | |||||
Cash ROIC |
(68.74%) | (75.15%) | (56.08%) | 0.00% | |
Accounts Receivable Turnover |
20.20 | 15.40 | 32.85 | 0.00 | |
Accounts Payable Turnover |
0.73 | 0.58 | 0.66 | 0.00 | |
Inventory Turnover |
1.29 | 0.75 | 0.70 | 0.00 | |
Average Days of Payables |
723.47 | 792.71 | 650.67 | 0.00 | |
Days of Inventory on Hand |
280.07 | 313.56 | 330.78 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | — | |
Research and Development Expense of Revenue |
478.02% | 463.31% | 403.77% | — | |
Selling, General and Administrative Expense of Revenue |
460.67% | 481.47% | 379.85% | — | |
Share Based Compensation of Revenue |
219.89% | 225.52% | 187.91% | — | |
Operating CF/Net income |
0.58 | 0.61 | 0.67 | — | |
Depreciation/Fixed assets |
0.07 | 0.11 | 0.15 | 0.00 | |
Capex/Depreciation |
0.00 | (1.58) | 2.02 | — | |
Revenue per Share |
0.01 | 0.01 | 0.01 | — | |
Operating CF per Share |
(0.05) | (0.05) | (0.05) | — | |
Capex per Share |
0.00 | 0.00 | 0.01 | — | |
Capex to Sales |
0.00 | 0.32 | (0.55) | — |
Columns are period end dates · fundamentals updated 6 Nov 2026